Drug Interactions between emapalumab and Vaxchora
This report displays the potential drug interactions for the following 2 drugs:
- emapalumab
- Vaxchora (cholera vaccine, live)
Interactions between your drugs
cholera vaccine, live emapalumab
Applies to: Vaxchora (cholera vaccine, live) and emapalumab
GENERALLY AVOID: The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections. In clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients receiving emapalumab. The reported infections were 41% viral, 35% bacterial, 9% fungal, while in 15% of cases the pathogen was not identified. The safety of immunization with live vaccines during or following emapalumab therapy has not been studied.
MANAGEMENT: The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.
References (1)
- (2018) "Product Information. Gamifant (emapalumab)." Sobi Inc
Drug and food interactions
cholera vaccine, live food
Applies to: Vaxchora (cholera vaccine, live)
ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.
MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.
References (4)
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2022) "Product Information. Dukoral (cholera vaccine, inactivated)." Valneva Sweden AB
- (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.